🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers Squibb Australia Pty Ltd

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. ,4-diaminopyridine

    Ultragenyx UK Limited

    Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

    phase 3 small molecule completed

    1 trial

  3. -, -, PACLITAXEL , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-2870, MK-2870, DOXORUBICIN , CAPECITABINE , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE , PARACETAMOL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  4. -, Apalutamide placebo, JNJ-56021927

    Janssen-Cilag International N.V.

    Metastatic Hormone-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

    Sanofi-aventis Healthcare Pty Ltd

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  6. -, DOCETAXEL , DEXAMETHASONE , -, -, MK-2870, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, PEMETREXED

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. -, IRINOTECAN , PARACETAMOL , -, -, PACLITAXEL , TRIFLURIDINE, COMBINATIONS, MK-2870, DOCETAXEL

    Merck Sharp and Dohme

    advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

    phase 3 small molecule active

    1 trial

  8. -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CAPECITABINE , PARACETAMOL , MK-2870, DEXAMETHASONE

    Merck Sharp and Dohme

    Triple negative breast cancer.

    phase 3 small molecule active

    1 trial

  9. -, PARACETAMOL , MK-2870, PACLITAXEL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CARBOPLATIN , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. -, TACROLIMUS , Amlitelimab, PIMECROLIMUS , Placebo, Amlitelimab

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  11. 0.2 mg/kg ketamine

    United Therapeutics Europe Ltd

    Depression

    phase 3 small molecule terminated

    1 trial

  12. 0.454% stannous fluoride

    Colgate Oral Care

    Oral Malodor

    phase 3 small molecule completed

    1 trial

  13. 0.454% stannous fluoride

    Colgate Oral Care

    Calculus, Dental

    phase 3 small molecule completed

    1 trial

  14. 0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection

    Celgene Europe Limited

    Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  15. 0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran

    Alnylam Netherlands B.V.

    High cardiovascular risk, Established cardiovascular disease, Hypertension

    phase 3 small molecule active

    1 trial

  16. 0.9% Saline, PARACETAMOL , Felzartamab, CETIRIZINE , LORATADINE , FAMOTIDINE , DIPHENHYDRAMINE , LEVOCETIRIZINE , DESLORATADINE , FEXOFENADINE , METHYLPREDNISOLONE

    Biogen

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  17. 0.9% Sodium Chloride Solution, Glenzocimab

    Pari Pharma GmbH

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  18. 0.9% Sodium Chloride for Injection, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  19. 0.9% Sodium Chloride, JNJ-78901563

    Xian-Janssen Pharmaceutical

    Invasive Extraintestinal Pathogenic Escherichia coli Disease

    phase 3 small molecule active

    1 trial

  20. 0.9% Sodium chloride, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  21. 0.9% sodium chloride, GB-0895

    Generate Biomedicines

    severe uncontrolled asthma

    phase 3 small molecule active

    1 trial

  22. 0.9% sodium chloride, Lepodisiran

    Eli Lilly Co.

    Atherosclerotic Cardiovascular Disease Elevated lp(a)

    phase 3 small molecule active

    1 trial

  23. 0.9% w/v sodium chloride solution for intravenous infusion, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  24. 1.0mg/kg/day PRAX-562

    Chongqing Precision Biotech Co., Ltd

    Developmental and Epileptic Encephalopathy 1

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources